JP2014509851A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509851A5
JP2014509851A5 JP2013557704A JP2013557704A JP2014509851A5 JP 2014509851 A5 JP2014509851 A5 JP 2014509851A5 JP 2013557704 A JP2013557704 A JP 2013557704A JP 2013557704 A JP2013557704 A JP 2013557704A JP 2014509851 A5 JP2014509851 A5 JP 2014509851A5
Authority
JP
Japan
Prior art keywords
npp1
fusion protein
npp1 fusion
acid residues
targeting moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013557704A
Other languages
English (en)
Japanese (ja)
Other versions
JP5735665B2 (ja
JP2014509851A (ja
Filing date
Publication date
Priority claimed from PCT/US2011/028233 external-priority patent/WO2011113027A2/en
Application filed filed Critical
Priority claimed from PCT/US2011/051858 external-priority patent/WO2012125182A1/en
Publication of JP2014509851A publication Critical patent/JP2014509851A/ja
Publication of JP2014509851A5 publication Critical patent/JP2014509851A5/ja
Application granted granted Critical
Publication of JP5735665B2 publication Critical patent/JP5735665B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013557704A 2010-03-12 2011-09-15 Npp1融合タンパク質 Active JP5735665B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34006610P 2010-03-12 2010-03-12
USPCT/US2011/028233 2011-03-11
PCT/US2011/028233 WO2011113027A2 (en) 2010-03-12 2011-03-11 Npp1 fusion proteins
PCT/US2011/051858 WO2012125182A1 (en) 2011-03-11 2011-09-15 Npp1 fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015084216A Division JP6096826B2 (ja) 2010-03-12 2015-04-16 Npp1融合タンパク質

Publications (3)

Publication Number Publication Date
JP2014509851A JP2014509851A (ja) 2014-04-24
JP2014509851A5 true JP2014509851A5 (https=) 2014-11-06
JP5735665B2 JP5735665B2 (ja) 2015-06-17

Family

ID=44564171

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013557704A Active JP5735665B2 (ja) 2010-03-12 2011-09-15 Npp1融合タンパク質
JP2015084216A Active JP6096826B2 (ja) 2010-03-12 2015-04-16 Npp1融合タンパク質
JP2017026961A Active JP6484905B2 (ja) 2010-03-12 2017-02-16 Npp1融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015084216A Active JP6096826B2 (ja) 2010-03-12 2015-04-16 Npp1融合タンパク質
JP2017026961A Active JP6484905B2 (ja) 2010-03-12 2017-02-16 Npp1融合タンパク質

Country Status (10)

Country Link
US (8) US8846603B2 (https=)
EP (1) EP2545080B1 (https=)
JP (3) JP5735665B2 (https=)
BR (1) BR112013023010B1 (https=)
CL (1) CL2013002607A1 (https=)
ES (2) ES2628841T3 (https=)
NZ (1) NZ615070A (https=)
SG (2) SG10202100341XA (https=)
TR (1) TR201903573T4 (https=)
WO (1) WO2011113027A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
KR20150038636A (ko) 2010-09-09 2015-04-08 시나게바 바이오파르마, 코포레이션 환자에서 리소좀 산 리파제 결핍증의 치료를 위한 리소좀 산 리파제의 용도
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
RU2601154C2 (ru) * 2011-03-11 2016-10-27 Синаджива Байофарма Корп Гибридные белки npp1
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
WO2014182666A1 (en) * 2013-05-06 2014-11-13 Bio-Rad Laboratories, Inc. Stabilization of labile analytes in reference materials
EP3967755B1 (en) 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
EP4414028A3 (en) 2015-05-19 2024-11-27 Yale University Compositions for treating pathological calcification conditions, and methods using same
EP3377105A4 (en) * 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
EP3471747A1 (en) * 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
CA3032467A1 (en) 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
CN120383683A (zh) * 2018-08-31 2025-07-29 耶鲁大学 Enpp1多肽及其使用方法
JP2023529557A (ja) * 2020-05-04 2023-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗enpp1抗体の阻害
WO2021252549A1 (en) 2020-06-09 2021-12-16 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
CA3184349A1 (en) * 2020-07-02 2022-01-06 Damon BANKS Compositions and methods for treating allograft vasculopathy, moyamoya disease, moyamoya syndrome and intimal proliferation
WO2025184419A1 (en) * 2024-02-29 2025-09-04 Kodiak Sciences Inc. Engineered complement inhibitor proteins

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
US6455495B1 (en) 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
US20040019923A1 (en) 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
JP2001520009A (ja) 1997-10-16 2001-10-30 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 鳥の導入遺伝子についてのマグナム特異的プロモーターを含むベクター
EP1032662B1 (en) 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
DE20121960U1 (de) * 2000-04-06 2004-01-15 Epigenomics Ag Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten
US20020108132A1 (en) 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US20090180989A1 (en) * 2005-10-05 2009-07-16 Synageva Biopharma Corp. Compositions and methods for delivering nucleotide sequences to vertebrates
HUE031655T2 (hu) 2007-05-11 2017-07-28 Alexion Pharma Inc Csontot targetáló alkálikus foszfatáz, készletek és eljárások alkalmazásukra
PE20100141A1 (es) * 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins

Similar Documents

Publication Publication Date Title
JP2014509851A5 (https=)
ES2342669T3 (es) Adzimas y usos de las mismas.
JP2005120106A5 (https=)
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
NZ615070A (en) Npp1 fusion proteins
JP2012522501A5 (https=)
JP2016527891A5 (https=)
HRP20161531T1 (hr) Fc fuzijski proteini koji sadrže nove linkere ili aranžmane
JP2017018125A5 (https=)
JP2018033454A5 (https=)
JP2015212284A5 (https=)
RU2018117558A (ru) Слитые иммуномодулирующие белки и способы их получения
RS64002B1 (sr) Anti-kancerski fuzioni polipeptid
JP2010273685A5 (https=)
JP2019527200A5 (https=)
JP2014511698A5 (https=)
JP2008301828A5 (https=)
FI2968461T3 (fi) Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi
HRP20221531T1 (hr) Pripravci faktora viii i postupci dobivanja i korištenja istih
JP2017512063A5 (https=)
JP2012095652A5 (https=)
JP2011501971A5 (https=)
JP2015524403A5 (https=)
RU2011144569A (ru) Мутанты индуцируемой активацией цитидиндеаминазы (aid) и способы их применения
JP2012025766A5 (https=)